secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2026-08-06T20:19:39+00:00
Accession:  0001193125-26-338097
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q2 2026 net loss $3.3M; cash $11.5M, runway into Q1 2027
-------------------------------------------------------------------------------

- Net loss of $3.3M ($0.87 per share) for Q2 2026 vs. $2.4M ($28.04) in Q2 2025.
- Cash and cash equivalents $11.5M as of June 30, 2026, up from $10.7M at Dec 31, 2025.
- Operating cash burn $2.6M in Q2 2026 vs. $1.9M in Q2 2025.
- Phase 2/3 AKI trial startup progressing; independent market assessment shows $94B TAM for Gemini.
- Management expects current cash to fund operations through Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/0001193125-26-338097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/revb-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer